CHE Quote, Financials, Valuation and Earnings

Health Catalyst, Inc. has a net margin of 10.28% compared to Chemed Corp.'s net margin of -29.13%. Chemed Corp.'s return on equity of 23.99% beat Health Catalyst, Inc.'s return on equity of -30.29%.

Chemed Corp. has a consensus price target of $555.50, signalling upside risk potential of 24.9%. On the other hand Health Catalyst, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 64.2%. Given that Health Catalyst, Inc. has higher upside potential than Chemed Corp., analysts believe Health Catalyst, Inc. is more attractive than Chemed Corp..

Chemed Corp. has a beta of 0.443, which suggesting that the stock is 55.685% less volatile than S&P 500. In comparison Health Catalyst, Inc. has a beta of 1.690, suggesting its more volatile than the S&P 500 by 69.042%.

Chemed Corp. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.5%. Health Catalyst, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed Corp. pays 9.05% of its earnings as a dividend. Health Catalyst, Inc. pays out -- of its earnings as a dividend. Chemed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed Corp. quarterly revenues are $624.9M, which are larger than Health Catalyst, Inc. quarterly revenues of $76.3M. Chemed Corp.'s net income of $64.2M is higher than Health Catalyst, Inc.'s net income of -$22.2M. Notably, Chemed Corp.'s price-to-earnings ratio is 23.51x while Health Catalyst, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed Corp. is 2.59x versus 0.51x for Health Catalyst, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Humana, Inc. has a net margin of 10.28% compared to Chemed Corp.'s net margin of 0.59%. Chemed Corp.'s return on equity of 23.99% beat Humana, Inc.'s return on equity of 7.3%.

Chemed Corp. has a consensus price target of $555.50, signalling upside risk potential of 24.9%. On the other hand Humana, Inc. has an analysts' consensus of $288.42 which suggests that it could grow by 8.31%. Given that Chemed Corp. has higher upside potential than Humana, Inc., analysts believe Chemed Corp. is more attractive than Humana, Inc..

Chemed Corp. has a beta of 0.443, which suggesting that the stock is 55.685% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.811%.

Chemed Corp. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.5%. Humana, Inc. offers a yield of 1.33% to investors and pays a quarterly dividend of $0.89 per share. Chemed Corp. pays 9.05% of its earnings as a dividend. Humana, Inc. pays out 35.45% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed Corp. quarterly revenues are $624.9M, which are smaller than Humana, Inc. quarterly revenues of $32.6B. Chemed Corp.'s net income of $64.2M is lower than Humana, Inc.'s net income of $194M. Notably, Chemed Corp.'s price-to-earnings ratio is 23.51x while Humana, Inc.'s PE ratio is 24.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed Corp. is 2.59x versus 0.25x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health, Inc. has a net margin of 10.28% compared to Chemed Corp.'s net margin of 3.61%. Chemed Corp.'s return on equity of 23.99% beat Option Care Health, Inc.'s return on equity of 15.16%.

Chemed Corp. has a consensus price target of $555.50, signalling upside risk potential of 24.9%. On the other hand Option Care Health, Inc. has an analysts' consensus of $37.91 which suggests that it could grow by 3.61%. Given that Chemed Corp. has higher upside potential than Option Care Health, Inc., analysts believe Chemed Corp. is more attractive than Option Care Health, Inc..

Chemed Corp. has a beta of 0.443, which suggesting that the stock is 55.685% less volatile than S&P 500. In comparison Option Care Health, Inc. has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.571%.

Chemed Corp. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.5%. Option Care Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed Corp. pays 9.05% of its earnings as a dividend. Option Care Health, Inc. pays out -- of its earnings as a dividend. Chemed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed Corp. quarterly revenues are $624.9M, which are smaller than Option Care Health, Inc. quarterly revenues of $1.4B. Chemed Corp.'s net income of $64.2M is higher than Option Care Health, Inc.'s net income of $51.8M. Notably, Chemed Corp.'s price-to-earnings ratio is 23.51x while Option Care Health, Inc.'s PE ratio is 29.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed Corp. is 2.59x versus 1.10x for Option Care Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx Corp. has a net margin of 10.28% compared to Chemed Corp.'s net margin of 2.99%. Chemed Corp.'s return on equity of 23.99% beat OptimizeRx Corp.'s return on equity of 0.03%.

Chemed Corp. has a consensus price target of $555.50, signalling upside risk potential of 24.9%. On the other hand OptimizeRx Corp. has an analysts' consensus of $24.33 which suggests that it could grow by 103.46%. Given that OptimizeRx Corp. has higher upside potential than Chemed Corp., analysts believe OptimizeRx Corp. is more attractive than Chemed Corp..

Chemed Corp. has a beta of 0.443, which suggesting that the stock is 55.685% less volatile than S&P 500. In comparison OptimizeRx Corp. has a beta of 1.087, suggesting its more volatile than the S&P 500 by 8.711%.

Chemed Corp. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.5%. OptimizeRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed Corp. pays 9.05% of its earnings as a dividend. OptimizeRx Corp. pays out -- of its earnings as a dividend. Chemed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed Corp. quarterly revenues are $624.9M, which are larger than OptimizeRx Corp. quarterly revenues of $26.1M. Chemed Corp.'s net income of $64.2M is higher than OptimizeRx Corp.'s net income of $779K. Notably, Chemed Corp.'s price-to-earnings ratio is 23.51x while OptimizeRx Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed Corp. is 2.59x versus 2.06x for OptimizeRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.